

# Giorgia Bodini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6399299/publications.pdf>

Version: 2024-02-01

107  
papers

2,065  
citations

257450

24  
h-index

265206

42  
g-index

110  
all docs

110  
docs citations

110  
times ranked

2682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 76-84.	1.9	6
2	Gastroesophageal reflux disease: key messages for clinicians. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.5	4
3	Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. <i>Gastrointestinal Disorders</i> , 2022, 4, 77-83.	0.8	0
4	Applicability of Parameters for the Noninvasive Diagnosis of Esophageal Varices Needing Treatment to Hepatitis C Virusâ€Cured Patients. <i>Clinical Infectious Diseases</i> , 2021, 72, 1862-1863.	5.8	1
5	Twoâ€Year effectiveness and safety of golimumab in ulcerative colitis: An IGâ€IBD study. <i>United European Gastroenterology Journal</i> , 2021, 9, 102-109.	3.8	8
6	Longâ€Term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <i>United European Gastroenterology Journal</i> , 2021, 9, 507-516.	3.8	11
7	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314.	3.2	10
8	Proactive Measures Aimed at Improving Appropriateness of Use of Proton Pump Inhibitors in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 410.	4.4	0
9	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368.	3.3	21
10	Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2142-2143.	1.3	7
11	Letter: predictive factors for treatment discontinuation in IBDâ€antiâ€TNF trough levels and antiâ€drug antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 536-537.	3.7	1
12	Therapeutic drug monitoring in Crohnâ€™s disease patients treated with anti-TNF. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	1.6	3
13	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	2
14	Letter: vedolizumab or a second antiâ€TNFâ€no difference in efficacy for primary biologic failures with IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1044-1045.	3.7	1
15	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohnâ€™s Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	1.3	65
16	Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV. <i>Annals of Hepatology</i> , 2020, 19, 222-225.	1.5	5
17	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402.	2.3	6
18	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	1.9	6

#	ARTICLE	IF	CITATIONS
19	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. <i>United European Gastroenterology Journal</i> , 2020, 8, 1228-1235.	3.8	16
20	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020, 12, 3363.	4.1	16
21	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	3.7	41
22	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. <i>Digestive and Liver Disease</i> , 2020, 52, 862-868.	0.9	11
23	Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 792-793.	0.9	0
24	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321.	2.4	26
25	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00177.	2.5	14
26	&lt;p&gt;Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data&lt;/p&gt;. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 99-104.	2.3	14
27	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1579-1587.	1.9	39
28	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 437-449.	3.1	21
29	Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13231.	3.4	8
30	Concerns related to COVIDâ€19 pandemic among patients with inflammatory bowel disease and its influence on patient management. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13233.	3.4	15
31	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohnâ€™s Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 451-456.	0.9	21
32	Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2020, 58, 208-213.	0.6	1
33	Study on the impact of Sexually Transmitted Infections (STIs) on quality of life, mood and sexual function. <i>Italian Journal of Dermatology and Venereology</i> , 2020, , .	0.2	0
34	Gastro-esophageal reflux disease: Key messages for clinicians. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, , .	2.2	4
35	A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 364-365.	0.4	1
36	OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e102.	0.9	0

#	ARTICLE	IF	CITATIONS
37	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019, 67-68, 110542.	2.4	42
38	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1220-1225.	1.5	6
39	OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e109.	0.9	0
40	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.9	25
41	Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 425-435.	3.0	10
42	P.07.4 HIGH ANTI-TNF ALFA DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e223.	0.9	0
43	P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S384-S385.	1.3	0
44	P576 Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn's disease patients treated with anti-TNF: a prospective multi-centre study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S402-S403.	1.3	1
45	Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand. <i>Liver Cancer</i> , 2019, 8, 524-526.	7.7	0
46	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019, 11, 2971.	4.1	57
47	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 79-88.	3.1	14
48	Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 546.	0.9	0
49	Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13056.	3.4	30
50	Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e73-e73.	1.9	3
51	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2019, 51, 640-647.	0.9	14
52	The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. <i>Journal of Gastroenterology</i> , 2019, 54, 261-270.	5.1	24
53	Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations. <i>Digestive and Liver Disease</i> , 2019, 51, 173-174.	0.9	2
54	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.	3.1	6

#	ARTICLE	IF	CITATIONS
55	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456.	0.9	22
56	Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients. <i>Annals of Hepatology</i> , 2018, 17, 830-835.	1.5	25
57	Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1123-1134.	3.1	112
58	Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm. <i>Liver International</i> , 2018, 38, 2101-2101.	3.9	1
59	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	17
60	High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation. <i>United European Gastroenterology Journal</i> , 2018, 6, 981-989.	3.8	55
61	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794.	2.4	24
62	NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 972-973.	3.7	4
63	Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13002.	3.4	13
64	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399.	0.9	46
65	Liver Stiffness Improvement Is Associated With Amelioration of Indirect Parameters of Portal Hypertension One Year After Sustained Virological Response to Direct Acting Antivirals in Chronic Hepatitis C Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, S577.	0.4	0
66	Granulocytes and monocytes apheresis induces upregulation of TGF $\beta$ 1 in patients with active ulcerative colitis: A possible involvement of soluble HLA. <i>Journal of Clinical Apheresis</i> , 2017, 32, 49-55.	1.3	8
67	Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. <i>Gastroenterology</i> , 2017, 152, S654.	1.3	0
68	Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. <i>Digestive and Liver Disease</i> , 2017, 49, 728-730.	0.9	18
69	Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , 2017, 49, 997-1002.	0.9	7
70	Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860-S861.	1.3	0
71	Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860.	1.3	0
72	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343.	1.8	39

#	ARTICLE	IF	CITATIONS
73	A Nodule, is a Nodule, is a Nodule: May Alpha-Fetoprotein Make the Difference?. American Journal of Gastroenterology, 2017, 112, 1340.	0.4	1
74	Vonoprazan fumarate for the management of acid-related diseases. Expert Opinion on Pharmacotherapy, 2017, 18, 1145-1152.	1.8	43
75	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lömann Index. Digestive and Liver Disease, 2017, 49, 175-180.	0.9	25
76	Epidemiology and natural history of gastroesophageal reflux disease. Minerva Gastroenterology, 2017, 63, 175-183.	0.5	30
77	Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohn's Disease Patients. American Journal of Gastroenterology, 2017, 112, S324.	0.4	1
78	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. American Journal of Gastroenterology, 2016, 111, 1037-1038.	0.4	1
79	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1081-1086.	1.5	36
80	Sa1933 Biological Therapy Is Able to Halt Crohn's Disease Progression: A Prospective, Long Term Study Using the Lömann Index. Gastroenterology, 2016, 150, S408.	1.3	0
81	Sa1877 Do Ulcerative Colitis Patients Treated With Corticosteroids at Diagnosis Really Have a More Aggressive Disease Course?. Gastroenterology, 2016, 150, S388.	1.3	0
82	Tu2009 Does Lömann Index Reflect the Quality of Life in Crohn Disease Patients on Treatment With Biological Therapy?. Gastroenterology, 2016, 150, S1004-S1005.	1.3	1
83	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1245-1245.	3.7	2
84	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. American Journal of Gastroenterology, 2016, 111, 1711-1717.	0.4	55
85	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1333-1341.	3.3	17
86	The natural history of gastro-esophageal reflux disease: a comprehensive review. Ecological Management and Restoration, 2016, 30, 1-9.	0.4	49
87	Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 1240-1241.	3.7	3
88	173 Esophagogastric Junction Morphology Assessment by High Resolution Manometry and Its Relationship With Gastroesophageal Reflux Disease in Obese Patients Candidate to Bariatric Surgery. Gastroenterology, 2016, 150, S44.	1.3	0
89	Esophageal testing: What we have so far. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 72.	1.0	26
90	Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?. Neurogastroenterology and Motility, 2015, 27, 1423-1431.	3.0	85

#	ARTICLE	IF	CITATIONS
91	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 292-293.	2.4	2
92	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 691.	2.0	11
93	Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1856.	4.4	1
94	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, 472-473.	0.4	6
95	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130.	2.4	2
96	Esophageal motility abnormalities in gastroesophageal reflux disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 86.	1.1	68
97	Letter: biological therapies are effective for prevention of postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 322-322.	3.7	3
98	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , 2014, 46, 1043-1046.	0.9	17
99	Gastrointestinal involvement in systemic sclerosis. <i>Presse Medicale</i> , 2014, 43, e279-e291.	1.9	59
100	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. <i>Journal of Gastroenterology</i> , 2014, 49, 1362-1363.	5.1	1
101	DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF- $\alpha$ levels and clinical outcome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42.	1.3	3
102	Prevention of Crohn's Disease Recurrence After Surgery: On the Road to Recovery. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1406.	4.4	0
103	Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, 1731-1742.	0.4	187
104	Prevention of postoperative recurrence of Crohn's disease by Adalimumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 24, 1.	1.6	21
105	Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 493-501.	3.7	30
106	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. <i>American Journal of Gastroenterology</i> , 2010, 105, 1053-1061.	0.4	190
107	Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 962-966.	2.2	59